Co-delivery of an HIV prophylactic and contraceptive using PGSU as a long-acting multipurpose prevention technology.

IF 5 2区 医学 Q1 PHARMACOLOGY & PHARMACY Expert Opinion on Drug Delivery Pub Date : 2023-02-01 DOI:10.1080/17425247.2023.2168642
Jarrod Cohen, Dennis Shull, Stephanie Reed
{"title":"Co-delivery of an HIV prophylactic and contraceptive using PGSU as a long-acting multipurpose prevention technology.","authors":"Jarrod Cohen,&nbsp;Dennis Shull,&nbsp;Stephanie Reed","doi":"10.1080/17425247.2023.2168642","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Poly(glycerol sebacate) urethane (PGSU) elastomers formulated with 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA), levonorgestrel (LNG), or a combination thereof can function as multipurpose prevention technology implants for prophylaxis against HIV and unintended pregnancies. For these public health challenges, long-acting drug delivery technologies may improve patient experience and adherence. Traditional polymers encounter challenges delivering multiple drugs with dissimilar physiochemical properties. PGSU offers an alternative option that successfully delivers hydrophilic EFdA alongside hydrophobic LNG.</p><p><strong>Methods: </strong>This article presents the formulation, design, and characterization of PGSU implants, highlighting the impact of API loading, dimensions, and individual- versus combination-loading on release rates.</p><p><strong>Results: </strong>Co-delivery of hydrophilic EFdA alongside hydrophobic LNG acted as a porogen to accelerate LNG release. Increasing the surface area of LNG-only implants increased LNG release. All EFdA-LNG, EFdA-only, and LNG-only formulated implants demonstrated low burst release and linear release kinetics over 245 or 122 days studied to date.</p><p><strong>Conclusion: </strong>PGSU co-delivers two APIs for HIV prevention and contraception at therapeutically relevant concentrations <i>in vitro</i> from a single bioresorbable, elastomeric implant. A new long-acting polymer technology, PGSU demonstrates linear-release kinetics, dual delivery of APIs with disparate physiochemical properties, and biocompatibility through long-term subcutaneous implantation. PGSU can potentially meet the demands of complex MPT or fixed-dose combination products, where better solutions can serve and empower patients.</p>","PeriodicalId":12229,"journal":{"name":"Expert Opinion on Drug Delivery","volume":"20 2","pages":"285-299"},"PeriodicalIF":5.0000,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Drug Delivery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17425247.2023.2168642","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 1

Abstract

Objectives: Poly(glycerol sebacate) urethane (PGSU) elastomers formulated with 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA), levonorgestrel (LNG), or a combination thereof can function as multipurpose prevention technology implants for prophylaxis against HIV and unintended pregnancies. For these public health challenges, long-acting drug delivery technologies may improve patient experience and adherence. Traditional polymers encounter challenges delivering multiple drugs with dissimilar physiochemical properties. PGSU offers an alternative option that successfully delivers hydrophilic EFdA alongside hydrophobic LNG.

Methods: This article presents the formulation, design, and characterization of PGSU implants, highlighting the impact of API loading, dimensions, and individual- versus combination-loading on release rates.

Results: Co-delivery of hydrophilic EFdA alongside hydrophobic LNG acted as a porogen to accelerate LNG release. Increasing the surface area of LNG-only implants increased LNG release. All EFdA-LNG, EFdA-only, and LNG-only formulated implants demonstrated low burst release and linear release kinetics over 245 or 122 days studied to date.

Conclusion: PGSU co-delivers two APIs for HIV prevention and contraception at therapeutically relevant concentrations in vitro from a single bioresorbable, elastomeric implant. A new long-acting polymer technology, PGSU demonstrates linear-release kinetics, dual delivery of APIs with disparate physiochemical properties, and biocompatibility through long-term subcutaneous implantation. PGSU can potentially meet the demands of complex MPT or fixed-dose combination products, where better solutions can serve and empower patients.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
使用PGSU作为长效多用途预防技术的HIV预防和避孕药物的联合交付。
目的:聚甘油癸二酸酯聚氨酯(PGSU)弹性体由4'-乙基-2-氟-2'-脱氧腺苷(EFdA),左炔诺孕酮(LNG)或其组合配制,可作为预防艾滋病毒和意外怀孕的多用途预防技术植入物。对于这些公共卫生挑战,长效给药技术可以改善患者体验和依从性。传统聚合物在传递具有不同物理化学性质的多种药物时遇到了挑战。PGSU提供了另一种选择,可以成功地提供亲水性EFdA和疏水性LNG。方法:本文介绍了PGSU植入物的配方、设计和特性,强调了API负载、尺寸以及单独与组合负载对释放率的影响。结果:亲水性EFdA与疏水性LNG共同递送可作为孔隙剂加速LNG释放。增加纯LNG植入物的表面积增加了LNG释放量。迄今为止,所有EFdA-LNG、EFdA-only和LNG-only配方植入物在245天或122天的研究中均表现出低爆发释放和线性释放动力学。结论:PGSU通过一个生物可吸收的弹性体植入物,在体外以治疗相关浓度递送两种用于HIV预防和避孕的api。作为一种新的长效聚合物技术,PGSU具有线性释放动力学,具有不同理化性质的原料药的双重递送,以及通过长期皮下植入的生物相容性。PGSU可以潜在地满足复杂MPT或固定剂量组合产品的需求,在这些产品中,更好的解决方案可以为患者服务并赋予患者权力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
11.10
自引率
3.00%
发文量
104
审稿时长
3 months
期刊介绍: Expert Opinion on Drug Delivery (ISSN 1742-5247 [print], 1744-7593 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles covering all aspects of drug delivery research, from initial concept to potential therapeutic application and final relevance in clinical use. Each article is structured to incorporate the author’s own expert opinion on the scope for future development.
期刊最新文献
Alternative routes for parenteral nucleic acid delivery and related hurdles: highlights in RNA delivery Sustained intra-cellular siRNA release from Poly(hypenCapswithspaceRetainColl1rginine) multilayered nanoparticles for prolonged gene silencing. Development of in vitro biopharmaceutics tools for predicting the bioavailability of subcutaneously injected monoclonal antibodies and oligonucleotides 3D printed personalized therapies for pediatric patients affected by adrenal insufficiency Redefining drug therapy: innovative approaches using catalytic compartments.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1